Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Next Previous
Search
Trial Profile

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 102 Mustang Bio (Primary) ; Cyclophosphamide; Decitabine; Fludarabine
  • Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Mustang Bio

    • Most Recent Events

    • 16 Jun 2023 Status changed from recruiting to discontinued due to business reasons.
    • 09 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2026.
    • 19 Dec 2022 According to a Mustang Bio media release, in 2023, company expects to provide information about Dose Level 2 after that level is fully enrolled and the SRT has reviewed the data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top